Kirn D - Search Results

1

Intravascular adenoviral agents in cancer patients: lessons from clinical trials.

Reid T, Warren R, Kirn D. Reid T, et al. Among authors: kirn d. Cancer Gene Ther. 2002 Dec;9(12):979-86. doi: 10.1038/sj.cgt.7700539. Cancer Gene Ther. 2002. PMID: 12522437 Free PMC article. Review.

2

Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.

Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D. Reid T, et al. Among authors: kirn d. Cancer Res. 2002 Nov 1;62(21):6070-9. Cancer Res. 2002. PMID: 12414631 Clinical Trial.

3

Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.

Mulvihill S, Warren R, Venook A, Adler A, Randlev B, Heise C, Kirn D. Mulvihill S, et al. Among authors: kirn d. Gene Ther. 2001 Feb;8(4):308-15. doi: 10.1038/sj.gt.3301398. Gene Ther. 2001. PMID: 11313805 Clinical Trial.

4

Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.

Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D. Reid T, et al. Among authors: kirn d. Gene Ther. 2001 Nov;8(21):1618-26. doi: 10.1038/sj.gt.3301512. Gene Ther. 2001. PMID: 11895000 Free PMC article. Clinical Trial.

5

Minimal hepatic toxicity of Onyx-015: spatial restriction of coxsackie-adenoviral receptor in normal liver.

Au T, Thorne S, Korn WM, Sze D, Kirn D, Reid TR. Au T, et al. Among authors: kirn d. Cancer Gene Ther. 2007 Feb;14(2):139-50. doi: 10.1038/sj.cgt.7700988. Epub 2006 Dec 1. Cancer Gene Ther. 2007. PMID: 17139321 Free PMC article. Clinical Trial.

6

Liver-directed viral therapy for cancer p53-targeted adenoviruses and beyond.

Warren RS, Kirn DH. Warren RS, et al. Surg Oncol Clin N Am. 2002 Jul;11(3):571-88, vi. doi: 10.1016/s1055-3207(02)00043-1. Surg Oncol Clin N Am. 2002. PMID: 12487057 Review.

7

A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.

Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM. Hecht JR, et al. Clin Cancer Res. 2003 Feb;9(2):555-61. Clin Cancer Res. 2003. PMID: 12576418 Clinical Trial.

8

Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval.

Breitbach CJ, Reid T, Burke J, Bell JC, Kirn DH. Breitbach CJ, et al. Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):85-9. doi: 10.1016/j.cytogfr.2010.02.001. Epub 2010 May 15. Cytokine Growth Factor Rev. 2010. PMID: 20472490 Review.

9

Oncolytic virotherapy for advanced liver tumours.

Chang JF, Chen PJ, Sze DY, Reid T, Bartlett D, Kirn DH, Liu TC. Chang JF, et al. Among authors: kirn dh. J Cell Mol Med. 2009 Jul;13(7):1238-47. doi: 10.1111/j.1582-4934.2008.00563.x. Epub 2008 Oct 23. J Cell Mol Med. 2009. PMID: 19175689 Free PMC article. Review.

10

A novel assay to assess primary human cancer infectibility by replication-selective oncolytic adenoviruses.

Wang Y, Thorne S, Hannock J, Francis J, Au T, Reid T, Lemoine N, Kirn D, Halldén G. Wang Y, et al. Among authors: kirn d. Clin Cancer Res. 2005 Jan 1;11(1):351-60. Clin Cancer Res. 2005. PMID: 15671566

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters